🚨随机试验：高剂量维生素C可将IV期胰腺癌患者的死亡风险降低54%，并将生存期延长一倍
在化疗中加入 75 克静脉注射维生素 C，与单独化疗相比，可使已知最致命的癌症之一的中位生存期延长一倍⬇️
患者按 1:1 的比例随机分组，分别接受吉西他滨加白蛋白紫杉醇单药治疗（n=16）或相同的化疗方案联合药理学静脉注射维生素 C（75 克，每周三次）（n=18）。
接受高剂量静脉注射维生素C治疗的IV期胰腺癌患者取得了显著疗效：
✅中位总生存期翻倍8.3 个月（单纯化疗） → 16 个月（化疗 + 静脉注射维生素 C）
✅死亡风险降低54%风险比：0.46
✅无进展生存期改善3.9 个月→ 6.2 个月
✅更高的客观缓解率23% → 38%
✅总体严重不良事件发生率较低
✅严重血液毒性（例如，中性粒细胞减少症）发生率较低
✅达到的药理学血浆维生素 C 水平（约 500 倍增加）
两组患者接受了相同的化疗方案，这意味着生存差异可归因于维生素 C 的添加。
对于一种中位生存期历来徘徊在 8-11 个月左右的疾病来说，生存期翻倍值得高度重视，并需要更大规模的验证性试验。
🚨RANDOMIZED TRIAL: High-Dose Vitamin C Cuts Death Risk from Stage IV Pancreatic Cancer by 54% and DOUBLES Survival Time
Adding 75g IV vitamin C to chemotherapy DOUBLED median survival compared with chemo alone — in one of the deadliest cancers known ⬇️
Patients were randomized 1:1 to receive either gemcitabine plus nab-paclitaxel alone (n=16) or the same chemotherapy regimen combined with pharmacologic IV vitamin C (75 g, three times weekly) (n=18).
The results were striking in patients with Stage IV pancreatic cancer who received high-dose IV vitamin C:
✅Median overall survival doubled8.3 months (chemo alone) → 16 months (chemo + IV vitamin C)
✅54% reduction in risk of deathHazard ratio: 0.46
✅Progression-free survival improved3.9 months → 6.2 months
✅Higher objective response rate23% → 38%
✅Lower rates of serious adverse events overall
✅Lower rates of severe hematologic toxicity (e.g., neutropenia)
✅Pharmacologic plasma vitamin C levels achieved (~500-fold increase)
Both groups received identical chemotherapy backbones, meaning the survival difference is attributable to the addition of vitamin C.
In a disease where median survival has historically hovered around 8–11 months, doubling survival warrants serious attention and larger confirmatory trials.
